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Abstract
Introduction: A common feature of neoplastic cells is that mutations in SMADs can contribute to the loss of
sensitivity to the anti-tumor effects of transforming growth factor-b (TGF-b). However, germline mutation analysis
of SMAD3 and SMAD4, the principle substrates of the TGF-b signaling pathway, has not yet been conducted in
breast cancer. Thus, it is currently unknown whether germline SMAD3 and SMAD4 mutations are involved in breast
cancer predisposition.
Methods: We performed mutation analysis of the highly conserved mad-homology 2 (MH2) domains for both
genes in genomic DNA from 408 non-BRCA1/BRCA2 breast cancer cases and 710 population controls recruited by
the Ontario site of the breast cancer family registry (CFR) using denaturing high-performance liquid
chromatography (DHPLC) and direct DNA sequencing. The results were interpreted in several ways. First, we
adapted nucleotide diversity analysis to quantitatively assess whether the frequency of alterations differ between
the two genes. Next, in silico tools were used to predict variants’ effect on domain function and mRNA splicing.
Finally, 37 cases or controls harboring alterations were tested for aberrant splicing using reverse-transcription
polymerase chain reaction (PCR) and real-time PCR statistical comparison of germline expressions by non-
parametric Mann-Whitney test of independent samples.
Results: We identified 27 variants including 2 novel SMAD4 coding variants c.1350G > A (p.Gln450Gln), and
c.1701A > G (p.Ile525Val). There were no inactivating mutations even though c.1350G > A was predicted to affect
exonic splicing enhancers. However, several additional findings were of note: 1) nucleotide diversity estimate for
SMAD3 but not SMAD4 indicated that coding variants of the MH2 domain were more infrequent than expected; 2)
in breast cancer cases SMAD3 was significantly over-expressed relative to controls (P < 0.05) while the case
harboring SMAD4 c.1350G > A was associated with elevated germline expression (> 5-fold); 3) separate analysis
using tissue expression data showed statistically significant over-expression of SMAD3 and SMAD4 in breast
carcinomas.
Conclusions: This study shows that inactivating germline alterations in SMAD3 and SMAD4 are rare, suggesting a
limited role in driving tumorigenesis. Nevertheless, aberrant germline expressions of SMAD3 and SMAD4 may be
more common in breast cancer than previously suspected and offer novel insight into their roles in predisposition
and/or progression of breast cancer.
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The BRCA1 and BRCA2 tumor suppressor genes have
been established as important high penetrance familial
breast cancer susceptibility alleles [1]. Rare mutations of
other tumor suppressor genes involved in direct pro-
tein-protein interaction with BRCA1/2 including TP53,
PTEN, CHEK2, ATM, NBS1, RAD50, BRIP1,a n dPALB2
were also discovered in breast cancer families, altogether
accounting for up to 50% of familial breast cancers [2,3].
On the other hand, rare germline alterations of potential
disease genes have not been investigated for the most
common non-familial (sporadic) form of breast cancer,
which accounts for the majority (70 to 80%) of all breast
cancers in the population.
Tumor suppressor genes known to be somatically
inactivated in breast cancers are particularly attractive
candidates. SMAD3 and SMAD4 are the key signaling
proteins of the transforming growth factor-b (TGF-b)
pathway and have been implicated to have tumor sup-
pressive effects in the pathogenesis of breast and other
cancer types [4,5]. The binding of TGF-b to TGFBI and
TGFBII receptors results in the activation of SMAD2/3
and hetero-complex formation with SMAD4 [6] and
mediates the regulation of genes involved in the sup-
pression of epithelial cell growth following nuclear
translocation. SMAD3 and SMAD4 possess two evolu-
tionarily conserved domains termed Mad-homology 1
(MH1) and 2 (MH2). The N-terminus MH1 domain is a
DNA-binding domain recognizing CAGA motifs. The
C-terminus MH2 domain is highly conserved and is one
of signal transduction’s most versatile protein-interact-
ing domain. It is involved in the interaction with
TGFBR1, formation of SMAD homomeric or hetero-
meric complexes, and transcriptional activation
(Reviewed in [7]).
The loss of SMAD3 expression and function is
involved in susceptibility to gastric cancers, colorectal
cancers and acute T-cell lymphoblastic leukemia [8-10].
Several lines of evidence suggest that SMAD3 may be
involved in breast cancer susceptibility. The SMAD3
locus on chromosome 15q21 has been shown to
undergo allelic imbalance [11]. In addition, SMAD3, like
many breast cancer susceptibility genes, is in direct pro-
tein-protein interaction with BRCA1 as it counteracts
BRCA1-mediated DNA repair [12] and its MH2 domain
has recently been shown to associate with BRCA1 dur-
ing oxidative stress response [13]. While inactivating
mutations in SMAD3 were previously believed to be
absent in all cancer types [14], a putative inactivating
missense mutation (R373H) was found in the colorectal
cancer cell line SNU-769A [15] as well as c.1009+1G >
A and c.1178C > T (P393L) from the screening of 38
primary colorectal cancers [16] both localized to the
MH2 domain.
SMAD4/DPC4 is a tumor suppressor gene, which is
mutated or deleted in half of all human pancreatic carci-
n o m a s[ 1 7 ]a n dl o s so fe x p r e s s i o n( L O H )h a sb e e n
shown to be important for the progression of gastric
[18], cervical [19] and colorectal [20] cancers. At least
15% of breast tumors exhibit LOH at the 18q21 locus
on which SMAD4 is situated [21] and breakpoints in
this region are associated with minimum copy number
[22] suggesting a tumor suppressor role. In addition to
pancreatic cancer, SMAD4 is somatically inactivated in
colon and biliary cancers [23], gastric cancer [24],
homozygous deletions of SMAD4 have been detected in
a small percentage of invasive ductal carcinomas [25,26].
In the germline, inactivating SMAD4 mutations are
found to be associated with approximately 20% of Juve-
nile Polypopsis Syndrome (JPS) cases [27,28]. Conse-
quently, mutation analyses in many cancers have
highlighted the MH2 domain of SMAD4 as a mutational
hotspot [29].
Presently, it is not known whether SMAD3 and
SMAD4 germline alterations are involved in breast can-
cer predisposition. Here, we aimed to explore the muta-
tion spectrum of SMAD3 and SMAD4 by screening the
highly conserved MH2 domain in the germline DNA in
familial and non-familial breast cancer cases as well as
age, gender and ethnicity matched healthy population
controls.
Materials and methods
Study population
Although considered different, familial and sporadic
forms of breast cancers have been shown to have com-
mon biological mechanisms, affecting similar pathways
such as alterations to BRCA-associated function in both
forms [30]. For example, a considerable portion of
patients with triple negative breast cancers (that is,
those that do not express estrogen receptor (ER), pro-
gesterone receptor (PR), and the human epidermal
growth factor receptor HER2) might also carry BRCA1/
2 mutations [31-33]. Additionally, a fraction of the
breast cancers may be misclassified based on the trun-
cated family history; therefore, making a fuzzy line
between familial and sporadic cases. To represent a
breast cancer population sample that is not only spora-
dic or familial, we took advantage of the population-
based sample of the Ontario Familial Breast Cancer Reg-
istry (OFBCR), a participating site in the US NIH Breast
Cancer Family Registry (BCFR) [34,35].
Familial cases of OFBCR were sampled from probands
that met certain high-risk criteria, including having at
least one first-degree relative with breast and/or ovarian
cancer, with second degree relatives with breast and
ovarian cancer, or with additional cancers (for example,
prostate, pancreatic, and so on) in the first or second
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multiple breast and/or ovarian primaries, or Ashkenazi
Jewish background. The breast cancer cases that did not
meet the familial criteria listed above were classified as
non-familial (sporadic) breast cancer cases, which are
represented by the older patients with no family history
of breast cancer. All the familial breast cancer cases
included in this study were previously tested negative
for BRCA1/2 mutations. The age range of all participat-
ing women was 25 to 69 years, with an average age of
48.8 ± 9.26 years. Female non-cancer population con-
trols have been randomly identified using the listed,
residential telephone numbers for the province of
Ontario. Controls were frequency-matched to female
case probands based on their expected five-year age dis-
tribution and ethnicity (64% response rate). The registry
sample consists of about 90% Caucasian women and
healthy female population controls with the reference
age in the range of 23 to 69 with an average age of 49.1
± 9.55 years. Written informed consent was obtained
from all subjects, and Mount Sinai Hospital Research
Ethics Board approved the study protocol. Genomic
DNA was extracted from blood lymphocytes from a
total of 408 breast cancer (173 familial and 235 spora-
dic) and 710 non-cancer population controls (20% (141/
710) sharing a familial criteria) were randomly selected
and subjected to genetic analysis.
Genetic analysis
Polymerase chain reaction (PCR) was used to amplify
the exons and exon-intron boundaries of exons 7, 8, 9
and exons 8, 9, 10, 11 spanning the MH2 domains of
SMAD3 and SMAD4, respectively. Thermocycling con-
ditions and PCR primer sequences are summarized in
Table 1. PCR was carried out in 50 μl volume contain-
ing 10 ng of genomic DNA, 1xPCR Gold buffer, 25 ng
of each 10 mmol/l primer, 2.5 units of Taq DNA poly-
merase (AmplitaqGold; Perkin-Elmer, Branchbury, NJ,
USA). Thermocycling was carried out in a Bio-Rad
Dyad thermocycler (Mississauga, Ontario, Canada) and
evaluated on 1.5% agarose gels. To ensure proper forma-
tion of homo- and hetero-duplexes for subsequent
dHPLC analysis, PCR products were denatured again at
95°C for 3 minutes and re-natured for 30 minutes by
decreasing temperature from 95°C to 65°C.
The PCR amplicons were screened by denaturing
High-Performance Liquid Chromatography (dHPLC).
The optimal melting temperature was calculated using
the dHPLC Melt Program [36] and DNA from breast
cancer cell lines (MDA-MB453, MDA-MB468, TD47)
was used to optimize the running conditions to enhance
mutation detection sensitivity on the Transgenomic
WAVE 4500HT (Transgenomic Inc., Omaha., NE,
USA). Approximately 10 ng of DNA from cases and
population controls were analyzed. Samples with elution
profiles characteristic of hetero-duplexes were identified
using the Navigator 1.7.0 Software (Transgenomic Inc.,
Omaha., NE, USA). As an internal control, a fraction of
case and control samples were duplicated across our
study population to ensure accuracy of the results. All
samples with heteroduplex profiles were purified by
SAP/ExoI and direct sequencing was performed by The
Centre for Applied Genomics, The Hospital for Sick
Children, Toronto, Canada.
Nucleotide diversity
Nucleotide diversity and its standard deviation were cal-
culated under the assumptions of an infinite site neutral
allele model:
θ = k/aL, s(θ)=

aθL + b(θL)
2/aLa =
n 
i=2
1
(i − 1)
b =
n 
i=2
1
(i − 1)
2
w h e r eKi st h en u m b e ro fS N P si d e n t i f i e di nag e n o -
mic length, L base pairs and n is the number of alleles
analyzed.
Table 1 PCR and dHPLC conditions
PCR DHPLC
Gene Exon Domain Forward PCR Primer (5’to 3’) Reverse PCR Primer (5’ to
3’)
Amplicon
Size (bp)
Annealing
Temperature (°
C)
MgCl
(nM)
Melting
Temperatures
(°C)
SMAD3 7 MH2 CGGCAGTGCCCATTTCCCCTAC CTAATCCAATCACCTCCAGATT 450 60 3 60, 62.5
SMAD3 8 MH2 TATAAATGAGGCTGGTCTAGGG GACATGCCTACTACGACCGTAG 544 60 2 60.2, 62.2
SMAD3 9 MH2 GTTTAACTCTTTAAAGTCGACT ACAGCTGTTCATAACATCCACC 556 60 2 58
SMAD4 8 MH2 TTTAAGAACAGTGCTAAGTACT TTAAGATGGAGTGCTTACAAAT 566 60 4 51.5, 53.5
SMAD4 9 MH2 TTTAATTTTTCAATATTAAGCA TAGATTACTGATAATGTCAATA 411 54 4 51.5
SMAD4 10 MH2 TAATGAAACTGAGTTTTAAATAA ATTTTACCAATTCAAAAATGTCA 377 57 3 51, 53
SMAD4 11 MH2 CTTTAGCAGAGAAGTTATATGCT AATATATCTTCAGATTATAAACA 424 57 4 59
Polymerase Chain Reaction (PCR) cycle conditions: four minutes 94°C initial denaturation; 94°C for 30 seconds, 0.5 to 1 minute at specified temperature (Ta), 72°C
for 0.5 to 1 minute for 35 cycles; and a final extension step of seven minutes at 72°C. Where applicable, Denaturing High-Performance Liquid Chromatography
(DHPLC) was run at two melting temperatures to obtain optimal separation.
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Impact of missense variants on protein function was
assessed by evolutionary conservation analysis using
SIFT [37] and structure by PolyPhen [38] FastSNP [39]
was used to evaluate the effect of synonymous variants
on Exonic Splicing Enhancers (ESE) in alternative spli-
cing regulation. The effect of intronic variants on the
consensus donor site, acceptor site, branch point as well
as creation of cryptic sites were carried out by measur-
ing 5’ and 3’ splice site scores using Automated Splice
Site Analyses (ASSA) [40]. ASSA has been shown to be
as robust [41] as other prevalent splice predictors
NNSplice, SpliceSiteFinder, and MaxEntScan. All in
silico splicing analysis tools were run at default thresh-
old values and the outputs for wildtype versus variant
were documented.
Analysis of aberrantly spliced transcripts
A total of 37 mRNA samples, 18 for SMAD3 and 19 for
SMAD4, were extracted from the lymphocytes of cases
and controls harboring the rare genetic variants (defined
as < 5 times) identified in this study. Reverse-transcrip-
tion PCR (RT-PCR) primers targeting the flanking exons
of the MH2 domain of SMAD3 (exons 6, 9) and
SMAD4 (exons 8, 11) based on cDNA sequences [Gen-
Bank:NM_5902 and GenBank:NM_005359, respectively].
This assay was carried out using instructions provided
by SuperScript III One-Step RT-PCR System with Plati-
num Taq DNA Polymerase kit (Invitrogen Burlington,
Ontario, Canada). Conditions and primer sequences are
summarized in Additional file 1, Table S1. The RT-PCR
products were separated on a 1.5% agarose and a non-
denaturing 8% polyacrylamide gel (29:1) to ensure high
resolution of fragments, and sequence was confirmed by
direct sequencing of the gel-purified DNA.
Analysis of mRNA expression levels
Quantitative Real-time PCR (qPCR) was performed
using an ABI 7700 Sequence Detection System (PE
Applied-Biosystems Streetsville, Ontario, Canada) in
t h ep r e s e n c eo fS Y B R - g r e e ni na3 0μl reaction. The
SYBR-Green I core reagent protocol was followed and
all reagents were provided in the core reagent kit. Pri-
merBank [42] qPCR primers for SMAD3 (PrimerBank
ID 5174513a2) and SMAD4 (PrimerBank ID
4885457a2) were used. All reactions were run in tripli-
cates and incubated in a 96-well optical plate at 95°C
for 10 minutes, followed by 40 cycles of 95°C for 15 s
and 60°C for 10 minutes. Standard curves were gener-
ated using 10-fold dilutions of pooled cell-line cDNA.
b-actin (Forward5’ATCATGTTTGAGACCTTCAA3’,
Reverse 5 CATCTCTTGCTCGAAGTCCA3’) was cho-
sen as a standard reference gene for the assay for
normalization.
mRNA expression analysis in normal breast and
carcinoma tissues
The cDNA expression data from breast tumor tissues of
50 patients with invasive ductal carcinoma (IDC) and 10
samples of normal breast tissue taken from surrounding
healthy breast tissue of cancer patients [43] were down-
loaded from ArrayExpress (accession number: E-TABM-
276). Five probes (239448_at, 218284_at, 205396_at,
s05397x_at, s05398_s_at) for SMAD3 and two
(202527_s_at, 1563703_at) for SMAD4 from the Affyme-
tricGeneChipU133 Plus 2.0 arrays were available.
Identification of somatic mutations in cancer
The COSMIC database v44 release is a project that cata-
logues homozygous or heterozygous somatic missense
mutations and deletions in various cancer types based
on curated research publications [44]. Using this
resource we reviewed the number of currently known
somatic mutations of SMAD3 and SMAD4 in breast,
colorectal and pancreatic cancers.
Statistical analysis
Statistical analysis of germline expression with t-test,
and non-parametric Mann-Whitney test of independent
samples were performed using SPSS v.13.0 (SPSS Inc,
Chicago, IL, USA) Statistical significance was assumed
at P < 0.05. Fold change in tumor versus normal tissue
expression was determined by two independent samples
t-test and Levin’s test for the equality of variance on the
mean expression levels.
Results
SMAD3 and SMAD4 germline alterations are primarily
intronic
We identified a total of 11 and 16 distinct genetic var-
iants in the MH2 domains of SMAD3 and SMAD4,
respectively (Table 2). SMAD3 variants were detected in
0.25% (1/408) of cases, 0.98% (7/710) of controls and
0.27% (3/1,118) in cases and controls and all were intro-
nic variants in the form of single base substitutions or
small deletions. The frequency of variants in SMAD4
was found to be 0.98% (4/408) in only cases and 1.13%
(8/710) in only controls, and 0.36% (4/1,118) present in
both cases and controls. Among these were three coding
variants in SMAD4 including c.1214T > C (p.Phe362Phe;
rs1801250) found in a case and control, and two novel
variants c.1350G > A (p.Gln450Gln) and c.1701A > G
(p.Ile525Val) from a case and control, respectively
(Table 2).
Nucleotide diversity estimation
Under the neutral theory of molecular evolution and
infinite sites model, sequence diversity can be estimated
by the heterozygosity per nucleotide site (π), termed
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Both are correct for sample size and the length of region
screened [45,46] and are nearly equivalent. We reported
θ and compared our data to other gene sets including
the coding and adjacent non-coding regions of 106
genes from clinically relevant pathways including cardio-
vascular, neuropsychiatry, endocrinology in 57 indivi-
duals by Cargill et al. [47], the 5’ and 3’ UTR, intron,
and coding region of 75 candidate genes involved in
blood pressure homeostasis in 74 individuals by
Halushka et al.[ 4 8 ] ,a n dt h er a t eo fp o l y m o r p h i s m si n
the coding regions and 3’ UTR of highly conserved and
essential genes involved in DNA replication and tran-
scription by Ten Asbroek et al. [49] (Additional file 1,
Table S2a, b). Results reported for the European/Ameri-
can ethnic subgroups were used where applicable.
The frequency of coding variants of SMAD3 in cases
and controls (θ = 0) was significantly lower compared to
SMAD4 (θ =3 . 9 9×1 0
-4 and 3.71 × 10
-4, respectively)
(Table 3) and lower than expected when compared to
rates observed by Cargill et al., (θ =5 . 4 3×1 0
-4), Halushka
et al., (θ =4 . 5×1 0
-4)a n dT e nA s b r o e ket al.( θ =2 . 0 0×
10
-4). For SMAD4,t h eθ values for coding variants in cases
and controls (θ =3 . 9 9×1 0
-4 and 3.71 × 10
-4, respectively)
is comparable to that reported by Cargill et al., (θ = 5.43 ×
10
-4) and Halushka et al., (4.5 × 10
-4), with standard devia-
tions overlapping, indicating that SMAD4 is not preferen-
tially altered in the germline for breast cancer.
The frequency of the non-coding SMAD3 and SMAD4
variants from cases and controls was higher than values
reported by Cargill et al., Halushka et al.w h e nc o n s i d -
ering the value reported for the European-American
samples, and the 3’UTR region reported by Ten Asbroek
et al. (Table 3). However, this may be simply due to the
difference in the study design, where up to 150 bp of
the non-coding exon-intron boundaries were covered in
this study compared to < 18 bp in the reference studies.
In silico analyses indicate potential mechanisms of
inactivation
Detailed results for bioinformatic analyses of ASSA and
FastSNP are summarized in Additional file 1, Table S3.
Table 2 Germline variants detected in SMAD3 and SMAD4 in breast cancer
Gene Exon Variants # Times (%) RefSnp (rs) number Case/Control In silico Prediction
SMAD3 9 IVS9+132A > T 1 (0.25%) Novel Case No effect
SMAD3 7 IVS6-132 C > T 1 (0.18%) Novel Control No effect
7 IVS7+69 G > C 4 (0.72%) rs58056680 Control No effect
8 IVS8-48 T > G 4 (0.72%) Novel Control No effect
8 IVS8+161 C > T 1 (0.18%) Novel Control No effect
9 IVS8-211 C > T 1 (0.18%) rs56264428 Control No effect
9 IVS8-170 C > T 1 (0.18%) Novel Control No effect
9 IVS8-55 A > G 2 (0.36%) rs28410524 Control Abolish branch site
SMAD3 7 IVS6-113 G > T 7 (1.72%); 15 (2.11%) rs2289791 Case & Control No effect
7 IVS6-95 T > C 4 (0.98%); 15 (2.11%) rs2289790 Case & Control No effect
8 IVS8+23 A > C 2 (0.49%); 5 (0.70%) rs55678244 Case & Control No effect
SMAD4 9 IVS9+118A > G 1 (0.25%) Novel Case No effect
10 IVS10+41G > A 1 (0.25%) Novel Case No effect
10 c.1350G > A/p.Gln450Gln 1 (0.25%) Novel Case Loss of ESE motifs
11 IVS10-33T > A 1 (0.25%) Novel Case Cryptic branch site
SMAD4 8 IVS7-121 A > C 1 (0.18%) Novel Control No effect
8 IVS8+44 T > C 1 (0.18%) rs28539779 Control No effect
9 IVS9+43delTT 1 (0.18%) Novel Control No effect
9 IVS9+68delGAA 1 (0.18%) Novel Control No effect
9 IVS9+126 del7 1 (0.18%) Novel Control Cryptic branch site
SMAD4 11 IVS10-52 A > T 1 (0.18%) Novel Control Cryptic donor
11 c.1701A > G/p.Ile525Val 1 (0.18%) Novel Control No effect
11 IVS11+53 A > G 1 (0.18%) Novel Control No effect
SMAD4 8 c.1214T > C/p.Phe362Phe 1 (0.25%); 1 (0.18%) rs1801250 Case & Control Loss of ESE motifs
8 IVS8+109 A > G 1 (0.25%); 3 (0.42%) Novel Case & Control Cryptic donor
10 IVS10+132delA 3 (0.74%); 2 (0.28%) Novel Case & Control No effect
11 IVS11+11 C > T 8 (1.96%); 11 (1.55%) rs1163402 Case & Control No effect
Note: Variant description is based on HGVS nomenclature. Nucleotide positions were numbered based on genomic sequences of SMAD3 [GenBank:NC_000015.8]
and SMAD4 [GenBank:NC_000018.8]. The cDNA sequences referenced were based on nucleic acid sequences for SMAD3 [GenBank:NM_5902] and SMAD4
[GenBank:NM_005359].
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> G, identified in two population controls was predicted
to abolish a branch site (Table 2). Four of the 16 identi-
fied SMAD4 variants were predicted to create cryptic
sites (Table 2). The SMAD4 variants, c.1350G > A (p.
Gln450Gln) (P9) found in a patient with familial breast
cancer and c.1214T > C (p.Phe362Phe) from a familial
breast cancer case and a control, were predicted to
result in the disruption of exonic splicing enhancers
(ESE).
Altered expression but no cryptic site formation in breast
cancers
In addition to the seven potential mutations predicted to
be functional, all the rarelyo c c u r r i n gv a r i a n t si no u r
population were assessed by RT-PCR for a thorough
investigation of both the effect of the predicted splicing
mutants and alterations on intronic structures such as
ISS/ISE, which presently cannot be reliably predicted in
silico a n dm i g h to t h e r w i s eb em i s s e d .H o w e v e r ,t h eg e l
electrophoresis of the PCR products showed the absence
of aberrantly spliced transcripts in the mRNA panel
studied.
For the qPCR analysis, cDNA harboring SMAD3 and
SMAD4 variants were categorized as breast cancer cases
with variants (BC-VAR) and controls with variants (CO-
VAR). As the case/control samples with SMAD3 var-
iants were negative for SMAD4 variants and vice versa,
each was used as a negative control for the other to
increase the power of the analysis (denoted BC-REF,
CO-REF).
SMAD3 expression levels in breast cancers harboring
variants (BC-VAR; n = 3) were significantly higher com-
pared to CO-VAR (n = 11; P = 0.038) and CO-REF (n =
12; P = 0.035) (Figure 1a). However, the SMAD3 var-
iants of the MH2 domain presented here do not seem
to be a strong driving force for the observed change in
expression. IVS8+23A > C was found in two cases (P1,
P8) with a large six-fold expression increase in P8 but
unchanged in P1 (Table 4; Additional file 1, Table S4a)
and IVS9+132A > T from P4 showing a 2.39-fold
increase (BC-VAR group mean: 3.19 ± 0.78). Particu-
larly, P5 in SMAD3 BC-REF (n = 5) had a very high
increase in expression (> 12-fold) without the presence
of an MH2 variant (BC-REF group mean 3.83 ± 0.78).
Nevertheless, significantly higher mean expression levels
in the grouped breast cancer (BC) versus control (CO)
(P = 0.02) (data not shown), strongly suggests SMAD3
germline expression to be an important factor in breast
cancer.
The SMAD4 variants predicted to create cryptic sites
or abolish branch sites did not result in aberrant expres-
sion patterns, consistent with the RT-PCR results. How-
ever, BC-VAR, but not BC-REF, exhibited significant
up-regulation in expression relative to CO-REF (n =1 1 ;
P = 0.036), CO-VAR (n = 13; P = 0.037) (Figure 1b;
Additional file 1, Table S4b). Among the BC-VAR
group (mean: 1.96 ± 0.42) were P2 (IVS12 + 41G > A)
and P5 (IVS11 + 118A > G), which showed a moderate
two-fold increase in expression. Of note, P9 harboring
c.1350G > A (p.Gln450Gln) from a familial breast can-
cer case (Table 4) predicted to disrupt ESE motifs was
associated with a level of high expression (> 5-fold) that
was not seen in any of the sample studied.
Somatic mutations in SMAD3 and SMAD4
According to COSMIC, no SMAD3 mutations were
reported based on 48 breast tumors screened while two
SMAD3 homozygous mutations were identified from 38
colorectal tumors. SMAD4 somatic mutations were clus-
tered in the MH2 domain supporting the observation
that the MH2 domain is a mutation hotspot in many
cancer types. For breast cancer the four homozygous
whole gene deletions represented the 2.8% of mutations
identified from the screening of 141 tumor samples,
while 10.7% (92/858) and 21.8% (123/564) were tumori-
genic mutations of the large intestines and pancreas,
respectively.
Expressions of SMAD3 and SMAD4 are up-regulated in
breast carcinoma
Using publically available online tissue expression data
[40], SMAD3 and SMAD4 expression in breast tumors
versus normal breast tissue were assessed using two
independent samples t-test and Levin’st e s tf o rt h e
equality of variance. SMAD3 and SMAD4 mRNA
Table 3 Nucleotide diversity (θ ×1 0
-4)
Nucleotide Diversity (θ)×1 0
-4 (Std Dev)
SMAD3 SMAD4 Cargill et al. [44] Halushka et al. [45] Ten Asbroek et al. [46]
Cases Controls Cases Controls
Non-coding 13.24 ± 7.02 11.24 ± 4.00 7.56 ± 3.36 11.71 ± 4.17 5.3 ± 1.33 5.4 ± 1.5 * 5.7 ± 1.9 **
Coding 0 0 3.99 ± 2.91 3.71 ± 2.69 5.43 ± 1.36 4.5 ± 1.2 * 2.00 ± 0.61
Total 3.54 ± 1.88 8.23 ± 2.93 6.18 ± 2.44 8.61 ± 2.86 5.39 ± 1.36 8.27 ± 1.9 2.00 ± 0.61
Note: Values are mean ± SD. Due to the fact that the Halushka et al. study was split into half African ethnicity and half north American of European descent, only
the coding/non-coding data from the European/American samples subset (*) are used for the purpose of this comparison. Please note we used θ in 3’ UTR for
non-coding data for Ten Asbroek et al. study (**) as they did not perform any analysis on intronic sequences.
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Figure 1 Quantitative Real-Time PCR analysis of SMAD3 and SMAD4 germline expressions. The mean expressions of four separate groups
of mRNA are compared for (A) SMAD3 and (B) SMAD4. The BC-VAR (Breast Cancer-Variants) group represents cases harboring variants; the BC-
REF (Breast Cancer - Reference) group represents the cases where variants were not detected. The CO-VAR (Control-Variants) group represents
controls harboring variants; CO-REF (Control-Reference), represents controls where variants were not detected. P5 and P9 represent familial breast
cancer cases exhibiting high germline expression with the latter harboring the novel c.1350G > A alteration. Statistical significance was
determined by the Mann-Whitney test of independence with error bars representing standard deviation (SD). The upper and lower boundaries
of the box indicate 75th and 25th percentiles, respectively. The line within the box represents the median; bars above and below the box, the
90th and 10th percentiles, respectively.
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Page 7 of 13expression levels were found to be significantly elevated
in the tumor tissues compared to normal tissues for
four of five probes (> 5-fold average increase, P < 0.05)
and one of two probes (> 10-fold increase, P < 0.01)
(Figure 2).
Discussion
BRCA1 and BRCA2 are the most prominent breast can-
cer susceptibility genes. However, there remains a need
to identify additional susceptibility genes as it has
become increasingly evident that BRCA1/BRCA2 muta-
tions cannot explain all cases of familial breast cancer.
Two candidate genes that are of potential interest in
clinical genetics of breast cancer are SMAD3 and
SMAD4, encoding the key signaling transduction pro-
teins of the Transforming Growth Factor-b (TGF-b)
pathway. The loci on which they reside are frequently
lost in breast cancer but whether germline variants are
Table 4 Clinical characteristics of 37 cases or controls with germline variants
Variant Detected
Patient ID Age Familial* SMAD3 SMAD4
P1 53 OFBCR IVS8+23A > C None
P2 57 None IVS12+41 G > A
P3 39 OFBCR None IVS10+109 A > G
P4 45 OFBCR/FDR IVS9+132 A > T None
P5 44 None IVS11+118 A > G
P6 51 OFBCR None IVS12-33 T > A
P7 47 None IVS12 +132 delA
P8 N/A OFBCR/FDR IVS8+23A > C None
P9 N/A OFBCR None c.1350G > A/p.Gln450Gln
C1 44 None IVS10+44 T > C, IVS11+106del7N
C2 44 None IVS11+68 delGAA
C3 42 IVS8+23A > C None
C4 37 None IVS10+109 A > G
C5 49 None IVS12 +132 delA
C6 34 IVS8-211 C > T None
C7 43 None IVS12-52 A > T
C8 43 OFBCR/FDR IVS8+23A > C None
C9 54 IVS8+23A > C None
C10 45 IVS6-132C > T None
C11 50 IVS7+69G > C None
C12 52 None c.1214T > C/p.Phe362Phe **
C13 47 None IVS9-121 A > C
C14 50 IVS8+161C > T IVS10+109 A > G
C15 31 OFBCR/FDR none IVS10+109 A > G
C16 35 IVS8+23A > C None
C17 48 IVS8+23A > C None
C18 46 IVS8+48T > G None
C19 43 IVS7+69G > C, IVS8-55 A > G None
C20 46 None IVS13+53 A > G
C21 45 IVS8-170C > T None
C22 67 IVS8+48T > G None
C23 49 None IVS10-121 A > C
C24 37 None c.1701A > G/p.Ile525Val
C25 52 IVS7+69G > C, IVS8-55 A > G None
C26 66 IVS7+69G > C None
C27 60 None IVS12 +132 delA
C28 62 None IVS12 +132 delA
Note: P represents a patient and C represents control
* The familial categorization is based on the OFBCR (Ontario Familial Breast Cancer Registry) and/or FDR (First Degree Relative) which indicates the strength of
familial association based on clinical history
** Found also in a case but mRNA was unavailable from the Breast Cancer Family Registry repository
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Page 8 of 13playing a role in predisposition of breast cancer has not
been studied.
For the discovery of the variants we applied the
dHPLC methodology, complemented by direct sequen-
cing, which has been reported to have over 95% sensitiv-
ity and accuracy in detecting genetic variations [50]. We
have targeted the analysis of the functionally critical
MH2 domain because it has been shown to be a muta-
t i o n a lh o ts p o ti nSMAD4 [29], the region where the
putative SMAD3 mutations had been identified [15,16]
and the region that interacts with BRCA1 [12]. Thus we
reasoned that a comprehensive screen of the exons
encoding the MH2 domain and surrounding intronic
region represents the most effective design to detect
novel SMAD3 and SMAD4 mutations.
Based on current understanding, mutations in SMAD3
are absent in almost all cancer types while mutations of
SMAD4 are frequent in pancreatic and colorectal
cancers but rare in breast cancer. However, it has been
difficult to ascertain whether SMAD3 and SMAD4
mutations in breast cancer are truly rare or this under-
standing is due to the comparatively small sample sizes
screened as noted from COSMIC. Furthermore, whether
inactivating germline mutations are playing a role in
breast cancer susceptibility has not yet been
investigated.
Our analysis did not detect coding variants in the
MH2 domain of SMAD3.I nSMAD4 we identified two
novel coding variants c.1350G > A (p.Gln450Gln) (P9),
and c.1701A > G (p.Ile525Val) (C24) in a breast cancer
case and control population, respectively, in addition to
the previously known c.1214T > C (Phe362Phe)
(rs1801250). As it has been suggested that SMAD3 and
SMAD4 mutations are rare in breast cancer [14,26], we
quantitatively assess whether this is the case in the
germline. The identified variants were normalized
Figure 2 SMAD3 and SMAD4 expression in breast carcinoma relative to normal tissue. Expression data were obtained from Affymetric
GeneChip U133 Plus 2.0 arrays for 50 tumors and 10 surrounding unaffected tissues. Statistical significance was determined by two independent
sample t-tests and Levin’s tests for the equality of variance.
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assessed (θ) and our case-control results were compared
to three large studies that have established an approxi-
mate frequency based on mutation analysis of germline
DNA of healthy individuals representative of the natural
rate of mutation.
We found that the nucleotide diversity in both cases
and controls in the coding region of SMAD3 to be far
less than all three reference studies. This difference is
not attributable to a discrepancy in sensitivity of detec-
tion of germline variants since there were comparable
frequencies for non-coding variants for both SMAD3
and SMAD4. This strongly supports that SMAD3 altera-
tion is very infrequent and suggests that the MH2
domain is under stringent selective pressure where dele-
terious mutations impeding proper function could also
negatively influence tumorigenesis. Within the coding
region of SMAD4, on the other hand, nucleotide diver-
sity estimations indicated that variants in cases and con-
trols appear to occur at a similar, albeit lower, rate than
the reference samples. This demonstrates that SMAD4
is not preferentially mutated in the breast, though rare
genetic alterations may exist in the MH2 coding region.
The non-coding regions have a higher θ compared to
the reference studies. However, it should be noted that
both the Cargill et al.a n dH a l u s h k aet al.s t u d i e s
remarked that their non-coding regions are comprised
of perigenic sequences (< 18 bp from the exon) while
our study spans up to 150 bp of the intron and may be
more representative of a neutral rate of polymorphism.
In fact, the study by Cargill et al. suggest that the θ for
four-fold degenerate sites reported in their study had
the highest nucleotide diversity (θ = 9.73 ± 2.46) and
may approximate the neutral rate of polymorphism. If
this θ is assumed to be the neutral rate of polymorphism
then what was observed in the non-coding regions of
SMAD3 and SMAD4 cases (θ = 13.24 ± 7.02, 7.56 ±
3.36, respectively) and controls (θ = 11.24 ± 4, 11.71 ±
4.17) would be in agreement.
Intronic variants, which constituted the major type
identified in this study, are increasingly found to be
associated with splicing defects (and ESE/ESS altera-
tions) causing cancer among other disorders [51]. How-
ever, RT-PCR analysis has shown the absence of any
aberrantly spliced transcripts, and no exon skipping was
observable in any sample, including the novel SMAD4
c.1350G > A variant (P9). It is also possible that the
aberrant transcripts are unstable and their degradation
may have occurred during the blood processing.
Although it is true that variants disrupting ESEs are
associated with decreased splicing efficiency and/or spli-
cing defect, there have been instances in which gain of
function ESE mutation strengthens the enhancer ele-
ment resulting in preferential exon inclusion. For
example, most mutations of microtubule-associated pro-
tein tau (MAPT) that are associated with (frontotem-
poral dementia and Parkinsonism associated with
chromosome 17 (FTDP17), a condition related to Alz-
heimer’s disease, are translationally silent but increase
splicing efficiency of exon 10 that increases the rate of
inclusion through strengthening ESEs at the 5’ end or
weakening ESS at the 3’ end [52]. In this regard the
c.1350G > A variant may be prioritized for further stu-
dies. Based on these results it appears inactivating
SMAD3 and SMAD4 germline mutations and splicing
defects appear to occur very infrequently in breast
cancer.
While the absence of inactivating MH2 germline
mutations from this study provides compelling evidence
that SMAD3 and SMAD4 mutations are truly rare in
breast cancer, this study cannot comprehensively
exclude the presence of other mutations since the Mad-
Homology 1 (MH1) and the variable linker region were
not screened. However, with respect to SMAD3,o u r
screening did not detect coding variants, within the
MH2 domain, including the ones previously identified in
colon and pancreas. Given that the SMAD3 mutations
are infrequent and that its expression is elevated in per-
ipheral blood and tumor tissues, SMAD3 does not seem
to be inactivated and is unlikely to contribute as a
tumor suppressor during breast cancer development.
With respect to SMAD4, 90% of all known somatic
SMAD4 mutations reported are located in the MH2
domain, suggesting that the number of undetected
mutations is expected to be low when analysis is con-
fined to this mutation hotspot. This is also supported by
mutation analysis conducted in JPS by Howe et al., [28]
showing that in 77 patients, inactivating germline
SMAD4 mutation were found in 18.2% (14/77) of the
samples and of these, 16.9% (13/77) occurred in the
MH2 domain. Similarly, mutation germline analysis by
Pyatt et al., [27] showed that SMAD4 is mutated in
18.6% (13/70) of the 70 JPS patients screened and of
these, 12.7% (9/70) occurred in the MH2 domain. Lastly,
a mutation screen of 56 patient thyroid tumor samples
by Lazzereschi et al. 2005 [53] identified SMAD4 MH1
mutations as well as linker mutations leading to splicing
defects. Nevertheless, the authors also found that more
than half (53% (8/15)) of the mutations were missense
mutations in the MH2 domain. By contrast, our study
of 408 patient samples and nucleotide diversity analysis
both show that inactivating MH2 domain mutations
appear to be absent. Thus, by inference the remaining
part of the gene is expected to harbor only very rare
mutations. It should be noted that germline biallelic
inactivations were not addressed in this study. For
SMAD4, homozygous deletion mutations have been
identified in invasive ductal carcinomas and it still
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germline homozygous deletions could be playing a sig-
nificant role in tumorigenesis. This possibility is cur-
rently under investigation.
Gene expression in peripheral blood cells has been
shown to be altered in early breast cancer but not
healthy controls [54,55]. To determine whether any of
the variants are associated with altered expression levels
we also performed expression analysis in the same sam-
ple set. Interpreting how changes in expression of
SMAD3 and SMAD4 affect their activities in the cell
may distinguish their roles as a tumor suppressor or
oncogene in breast cancer susceptibility.
There is strong evidence for tumor suppressor func-
tion of SMAD3 as its loss is associated with tumorigen-
esis in various cancers [8-10]. However, our qPCR
analysis showed that mRNA from breast cancer cases
was significantly highly expressed relative to both con-
trol groups (BC vs. CO; P < 0.05, t-test) but was not
due to the variants found in the breast cancer cases.
Thus, this observation is likely attributable to regulatory
factors beyond the MH2 domain. These results, together
with the lack of inactivating mutations from this study
and COSMIC database, strongly support that SMAD3 is
not functioning as a direct tumor suppressor in breast
cancer. Nevertheless the abnormally high levels of germ-
line expression as well as statistically significant over-
expression of SMAD3 in invasive ductal carcinoma
(IDC) compared to normal tissues raises the possibility
that epistatic interactions of SMAD3 may contribute to
the oncogenic activities of TGF-ß. SMAD3 has been
shown to counteract BRCA1-dependent DNA repair in
response to DNA damaging agents and over-expression
of SMAD3 decreases BRCA1-dependent cell survival
[12]. Therefore, it is possible that such high levels of
germline SMAD3 expression may mimic a BRCA1-defi-
cient phenotype. Furthermore, the aberrant expression
may be a mechanism that reconciles the allelic imbal-
ance often associated with the 15q21 locus in breast
cancer [11] with the apparent lack of SMAD3 inactivat-
ing mutations.
Loss of expression and allelic imbalance at the SMAD4
locus has been shown to promote carcinogenesis of gas-
tric, ovarian, and colorectal cancers [18,47,48]. Overall, in
our study SMAD4 cases were not differently expressed
compared to controls and the variants predicted to create
cryptic sites or abolish branch site did not result in aber-
rant expression. Interestingly, however, the breast cancer
case (P9) harboring the novel c.1350G > A variant in exon
10 of SMAD4, predicted to affect ESEs, had a significant
expression increase by almost five-fold that was not
observed in any other samples examined, indicating that
the full length transcript is preferentially over-produced.
Increasing SMAD4 germline expression is unlikely to
predispose to breast cancer due to its important role as a
tumor suppressor suggesting that SMAD4 is not involved
in susceptibility. However, it is appreciated that as tumori-
genesis develops the cell becomes increasingly desensitized
to the anti-proliferative effects of TGF-b but remains sus-
ceptible to its oncogenic properties. Therefore, c.1350G >
A could represent a potential prognostic marker as
SMAD4 expression has been shown to be an important
mediator in the development of osteolytic bone metastasis
in late cancer stages but is not required in its maintenance
or progression [56,57]. This is consistent with the fact that
although SMAD4 mRNA levels and protein expression
appear to be decreased in breast cancer relative to normal
tissues [58] they are not significantly correlated with
tumor size, metastases, nodal status, histological grade,
histological type, or estrogen receptor expression. In fact,
there was a trend toward longer survival times in patients
with SMAD4 negative tumors [58] and a loss of expression
is also correlated with a decrease in axillary lymph node
metastasis [59]. Thus, the results presented here highlight
a potential value for evaluating coding variants that affect
ESE/ESS for abnormal expression even if they do not
influence splicing.
Conclusions
This study has demonstrated that expression levels of
SMAD3 and SMAD4 are important factors in breast
cancer but have different consequences. Aberrant
SMAD3 germline expression rather than inactivating
mutations may be playing a major role in susceptibility.
While SMAD4 is not preferentially mutated in breast
cancer, rarely occurring variants, such as c.1350G > A,
probably serve as low to medium penetrating inherited
germline mutations with prognostic value. Despite the
fact that such expression-altering variants only account
for a small subset of the alterations observed, their
importance should not be underestimated since it is
possible that human cancers can possess many low-
penetrating alterations which, when acting synergisti-
cally, represent a powerful driving force of the carcino-
genic process. Future research to explore the
mechanisms of deregulation of SMAD3 and SMAD4
expressions will be essential in determining their asso-
ciation with breast cancer risk and tumorigenesis.
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